XTANDI® (enzalutamide), co-developed by Astellas and Pfizer, has shown a significant 30% reduction in risk of death over five years in metastatic hormone-sensitive prostate cancer (mHSPC) patients, marking it as the first androgen receptor inhibitor to demonstrate this long-term survival benefit.
Prostate Cancer
The test, which examines 18 genes, was created especially to identify malignancies that require rapid treatment as opposed to those that grow slowly.
Researchers made a substantial advancement in computational pathology and medical diagnostics by creating a machine-learning model to enhance prostate cancer biopsy evaluation.
